Corbus Pharma gets $25M grant, FDA nod for cystic fibrosis drug trial

Norwood-based Corbus Pharmaceuticals said Tuesday that it has received a $25 million grant from a cystic fibrosis research group to help fund an upcoming study of a drug targeting symptoms of the lung disease. Corbus (Nasdaq: CRBP) said that the development award from the Cystic Fibrosis Foundation would allow it to conduct a mid-stage study of its drug, called lenabasum. The nonprofit group also funded an earlier trial of lenabasum. Unlike cystic fibrosis treatments currently sold by Boston-based…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news